Stock Ratings / Health Care / GTBP / dividends

LSTA (29) GDTC (52) TVRD (32) ASBP (40) ⌘ Pro Terminal →

GT Biopharma Inc. (GTBP) Dividend Safety Gauge & 10-Year DRIP Compounder

$5.32 -5.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.26

GT Biopharma Inc. (GTBP) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $11.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GTBP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GTBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, GT Biopharma Inc. (NASDAQ: GTBP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $5.32 (-5.00% 1D, market cap $11.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, GTBP ranks #579 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GTBP compare to LSTA and GDTC in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GTBP carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LSTA (Lisata Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, GTBP leads on earnings multiple (N/A) while GTBP leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GTBP?

▼

Per GTBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000109657), GT Biopharma Inc. generated $0 in revenue, -$28.4M in net income, and -$12.9M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.26 (-1.09%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GTBP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY GTBP SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)

FRED Regime × Technicals: 23% of 52W Range • RSI-14 at 42 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$6.50+12.5% Next Q

Q2 (-2Q)

Grade D$7.31-23.7% Next Q

Q3 (-1Q)

Grade E$5.58-4.7% Next Q

Current

Grade D-$5.32-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GTBP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GTBP currently carries a cautious 36/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.68) and Max Pain ($5.59) forces dealer call-delta covering toward $22.71.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GTBP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GTBP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

3.78% Total Yield

1.98% Cash ($0.11/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

88/100 • FORTRESS PAYOUT

FREE CASH FLOW PAYOUT RATIO

46% of FCF

8 consecutive years of payout growth

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (8.7% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $23,030

Est. Year-10 Shareholder Yield: $871/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.9K

Yr 1

$11.8K

Yr 2

$12.8K

Yr 3

$14.0K

Yr 4

$15.2K

Yr 5

$16.5K

Yr 6

$17.9K

Yr 7

$19.5K

Yr 8

$21.2K

Yr 9

$23.0K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GTBP)

✓Walkthrough of GTBP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GTBP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.41%🛡️ HOLDING TREND SUPPORT

2026-11-03O $5.60H $5.60L $5.32C $5.32VOL 20.3K

RES: $10.77SUP: $5.10SMA50: $6.68SMA200: $9.62

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GTBP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GTBP Butterfly Map → + Track GTBP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GTBP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GTBP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GTBP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GTBP)

Health Care Rank #579 of 1016 ⚔️ LSTA vs GTBP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GTBP vs. LSTA, GDTC, TVRD, ASBP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, GT Biopharma Inc. (GTBP) ranks #579 by composite RQD confidence (36/100, grade D-) and #886 by equity capitalization ($11.0M). Within this direct 5-issuer industry benchmark cohort, GTBP leads on earnings valuation at N/A trailing P/E, while GTBP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GDTC currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with GTBP at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GTBP ACTIVE GT Biopharma Inc.	D-	36/100	—	—	-35.0%	-5.00%	$11.0M	Benchmark Subject
LSTA Lisata Therapeutics Inc.	E	29/100	—	—	-35.0%	+0.99%	$11.0M	/lsta-vs-gtbp →
GDTC CytoMed Therapeutics Limited	D+	52/100	—	—	—	+2.02%	$10.9M	/gdtc-vs-gtbp →
TVRD Tvardi Therapeutics Inc.	E	32/100	—	—	-35.0%	-8.13%	$10.6M	/tvrd-vs-gtbp →
ASBP Aspire-Lakewood Holdings Inc.	D-	40/100	—	-1.9%	-35.0%	-4.36%	$11.4M	/asbp-vs-gtbp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000109657

In its most recent audited fiscal period (FY2025, filed 2025-12-31), GT Biopharma Inc. (GTBP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$28.4M, operating cash flow of -$12.9M, and free cash flow of -$12.9M (-0.1% YoY). On the balance sheet, GTBP closed FY2025 with $8.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$28.4M	-$12.9M	-$12.9M	$8.1M	—
FY2024 (FY)	2024-12-31	$0	-$13.2M	-$12.9M	-$12.9M	$4.2M	—
FY2023 (FY)	2023-12-31	$0	-$7.6M	-$8.9M	-$8.9M	—	—

3. GTBP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GTBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does GTBP compare to LSTA and GDTC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for GTBP?

Where is GTBP trading relative to its 50-day, 200-day, and 52-week technical levels?

GTBP last traded at $5.32 (-5.00% on volume of 20,281 shares), positioning the stock -20.36% below its 50-day simple moving average ($6.68) and -44.70% below its 200-day simple moving average ($9.62). Across its 52-week range of $0.54 to $21.63, GTBP sits at the 22.7% percentile with a 14-day RSI of 42.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.65 to $5.99).

GTBP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does GTBP pay a dividend and is it safe?

GT Biopharma Inc. (GTBP) offers a 1.98% cash dividend yield ($0.11 annualized) and 3.78% total shareholder yield including buybacks. Roarable rates its payout coverage as FORTRESS PAYOUT.

Direct Sub-Reports: GTBP RQD Cockpit GTBP 12M Forecast GTBP Earnings & Move GTBP Dividends & DRIP GTBP Insiders & 13F GTBP Whale Options GTBP Profit Sankey GTBP News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GTBP — GT Biopharma Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:51:26Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, GTBP scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). The weakest pillars are the cash engine and institutional flow, which together indicate that the company is not currently generating cash from operations and that the data shows little supportive positioning from large holders. For a prospective investor evaluating the stock today, the implication is that the upside case rests on developments not yet reflected in reported cash flows, while the valuation and downside risk are elevated given a negative ROIC and zero free-cash-flow yield. The rating is an analytical summary of the supplied data and is not personalized advice.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-12.4M	$-28.4M	N/A	$-12.9M	$6.8M	N/A
FY 2024	$0.0M	$-14.4M	$-13.2M	N/A	$-12.9M	$4.0M	N/A
FY 2023	$0.0M	$-13.6M	$-7.6M	N/A	$-8.9M	N/A	N/A

Per the SEC financials, the company reported zero revenue and negative operating and net income across all three periods, with gross, operating, and net margins each shown as 0% in market data. ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the Roarable RQD forensic pillar. Debt/Equity is 0.5 per the same source. Reported cash rose from $4.0M to $6.8M between FY 2024 and FY 2025, while debt is shown as N/A in the financial table.

Recent Catalysts & News Wire Analysis

Per the recent news feed, all six items are tagged YELLOW with impact label MARKET WIRE:

A StockInvest.us forecast article titled around GTBP price outlook.
A Stock Titan item referencing an SEC filing dated Oct 21, 2026.
A Yahoo Finance item that references CNTB (Connect Biopharma) rather than GTBP.
A Stock Titan item on a pancreatic cancer immune-treatment study.
A Benzinga item listing GTBP among Health Care stocks moving intraday.
A GlobeNewswire item stating GT Biopharma was selected for an oral presentation at the SITC 2026 Annual Meeting.

The Butterfly Supply-Chain Graph reports supply_chain as NONE, with no butterfly links and no proprietary signals. Risk watch items include the unexplained SEC filing reference, the mixed-ticker Yahoo item, and general YELLOW-level market-wire tagging without quantified impact.

Open Questions

What is the source of the $0.0B market capitalization in the profile versus the $11.5M in market data?
Why are FY 2023 cash and all period debt figures shown as N/A, and what is the actual balance-sheet debt position?
What is the content of the Oct 21, 2026 SEC filing referenced in the news feed?
Does the SITC 2026 oral presentation reference relate to a specific pipeline asset, and what is its development stage?
Why does the Yahoo Finance item reference CNTB rather than GTBP, and does it affect the relevance of the news signal?

GTBP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for GT Biopharma Inc. (GTBP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GTBP Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 18h ago

Gt Biopharma Stock Price Forecast. Should You Buy GTBP?

StockInvest.us report covering GT Biopharma Inc. (GTBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 21h ago

GT Biopharma, Inc. SEC Filing (Oct 21, 2026) | GTBP EFFECT

Stock Titan report covering GT Biopharma Inc. (GTBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher

Yahoo Finance report covering GT Biopharma Inc. (GTBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A study on making pancreatic cancer more vulnerable to immune treatment gets an oral slot

Stock Titan report covering GT Biopharma Inc. (GTBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Wednesday's Intraday Session - Pomdoctor (NASDAQ:POM), Stablecoin Develop

Benzinga report covering GT Biopharma Inc. (GTBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting

GlobeNewswire report covering GT Biopharma Inc. (GTBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

AZR Stock Price and Chart — BOATS:AZR

TradingView report covering GT Biopharma Inc. (GTBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GTBP Bull vs. Bear Conversation Board — What's Your Call at $5.32?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GTBP 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $4.93 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is GTBP (D- • RQD 36/100) a Buy at $5.60?

Welcome to the GTBP (GT Biopharma Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.65 (-17.0%)

Spot @ $5.60

Pump the brakes on GTBP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GTBP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless GT Biopharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $6.72 (+20.0%)

Spot @ $5.60

GTBP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GTBP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $5.60 (52-wk range $0.54 - $21.63), any beat on forward guidance forces shorts and underweight funds to chase.